Post
CRISPR drug licensing deals secure $21bn in top three therapy areas over five years
Licensing agreements for innovator drugs utilising clustered regularly interspaced short palindromic repeats (CRISPR) technologies saw oncology, immunology, and central nervous system …
Xilio and Gilead partner up for IL-12 therapeutic development
Gilead Sciences and Xilio Therapeutics declared an exclusive license agreement for the development of a tumour-activated IL-12 program. Under the deal, …
Cheap drugs, inspections, and a future war in Europe – what’s driving drug shortages?
Drug shortages are worsening globally, leaving patients without access to essential medications, and healthcare providers struggling to find alternative treatments. …
Boundless Bio raises $100m as IPO market rouses
US-based Boundless Bio will offer 6,250,000 shares for $16 each as the oncology company hears the bell on the Nasdaq …
OSE Immunotherapeutics gets grant for anti-human SIRPA antibody for treating cancer
OSE Immunotherapeutics has been granted a patent for antibodies targeting human SIRPa, enhancing antigen presentation to T cells. The invention …
Abivax gets grant for antitumor pharmaceutical combination for cancer treatment
Abivax has been granted a patent for an antitumor pharmaceutical combination involving compound ABX196 and chemotherapeutic or immunotherapeutic agents for …
4D Molecular Therapeutics gets grant for recombinant aav for muscle cell infectivity with heterologous peptide
4D Molecular Therapeutics has been granted a patent for variant adeno-associated virus (AAV) capsid proteins that increase infectivity of muscle …
Atea Pharmaceuticals gets grant for treatment of covid-19 using purine nucleotide phosphoramidates
Atea Pharmaceuticals has been granted a patent for a method using purine nucleotide phosphoramidates to treat or prevent COVID-19 caused …
Spruce Biosciences gets grant for treatment of polycystic ovary syndrome with adrenal hyperandrogenism
Spruce Biosciences has patented a method for treating PCOS-FAH by administering a CRF1 antagonist. The treatment targets elevated adrenal androgens, …
Pieris Pharmaceuticals gets grant for patent granted for novel muteins derived from human lipocalin
Pieris Pharmaceuticals has been granted a patent for a novel library and muteins derived from human lipocalin 2 (Lcn2, hNGAL) …
Lantern Pharma gets grant for treatment of atypical teratoid/rhabdoid tumor using hydroxyureamethyl acylfulvene
Lantern Pharma has been granted a patent for a method to treat atypical teratoid/rhabdoid tumor by administering HydroxyUreaMethyl Acylfulvene to …
Denali Therapeutics gets grant for proteins for treating sanfilippo syndrome A
Denali Therapeutics has been granted a patent for proteins capable of crossing the blood-brain barrier and containing SGSH enzyme-Fc fusion …
Ikena Oncology gets grant for MEK inhibitors for cancer treatment
Ikena Oncology has been granted a patent for MEK inhibitors, compositions, and methods of use. The compound selection is a …
Cue Biopharma gets grant for T-cell modulatory multimeric polypeptides for immune response modulation
Cue Biopharma has developed T-cell modulatory multimeric polypeptides containing an immunomodulatory polypeptide and a Wilms tumor peptide to modulate T …
Equillium gets grant for inhibitors of cytokine activity using peptide antagonists
Equillium's patent involves peptide antagonists targeting ?c-family cytokines associated with diseases like leukemia and autoimmune disorders. The patent claims a …